Vogenx Begins Phase 2b EMERGE Trial of Mizagliflozin
The randomized, double-blind, placebo-controlled study will evaluate two doses in patients with recurrent hypoglycemia following bariatric surgery.
Story updates
08:37:34 PM UTC
SquawkNews
Vogenx, Inc. initiated EMERGE, a randomized, double-blind, placebo-controlled Phase 2b trial of mizagliflozin in post-bariatric hypoglycemia, enrolling ~36 U.S. patients to test 5 mg and 10 mg TID for 28 days with hypoglycemic events as the primary endpoint.Material DetailsContext by AI AnalystThis…